BioAge, a Richmond, California–based biotechnology firm, has secured $90 million in an oversubscribed Series C funding round, according to the company. The financing was co‑led by Andreessen Horowitz and Elad Gil, and included participation from Kaiser Foundation Hospitals, AARP Foundation’s RockCreek Impact Fund, Phi‑X Capital, along with existing investors such as Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, and Felicis Ventures.
The proceeds will be used to further develop BioAge’s systems‑biology and data‑driven platform aimed at mapping molecular pathways linked to human aging, and to build out its pipeline of therapies targeting those pathways.
According to the company, the funding will support the progression of its two lead platform‑derived small molecules, BGE‑117 and BGE‑175, into Phase 2 clinical trials, anticipated in the first half of 2021.
The company said that it has appointed Dr. Paul Rubin as chief medical officer. Rubin brings extensive clinical development experience from roles at Sepracor, GSK, Abbott, MiRagen, and Xoma, and is expected to oversee its clinical strategy.
BioAge says its proprietary platform leverages decades of longitudinal human cohort data—including omics and medical follow‑up—to identify molecular drivers of aging and prioritize therapeutic targets. The company claims this engine enables discovery of drugs designed to extend healthspan and lifespan by addressing age‑related pathologies.
Since its founding in 2015, BioAge has raised a total of approximately $127 million in venture capital, the company confirmed.
